NEW YORK – Carrick Therapeutics and Roche announced a clinical collaboration on Monday to study Carrick's samuraciclib and Roche's giredestrant in CDK4/6 inhibitor resistant HR-positive, HER2-negative metastatic breast cancer.
The two firms will begin a Phase Ib/II study evaluating the combination treatment using Roche's Morpheus platform, which helps accelerate development of combinations for certain cancers. Samuraciclib is a CDK7 inhibitor and giredestrant is an estrogen receptor degrader.
"Carrick's preclinical studies have shown strong synergy combining CDK7 inhibitors with endocrine therapies, including models of resistance to CDK4/6 inhibitors," Carrick CEO Tim Pearson said in a statement. "This collaboration represents a shared commitment to maximize the potential of innovative combination treatment approaches and address significant unmet needs."
Carrick is also studying samuraciclib in another trial in CDK4/6 inhibitor resistant HR-positive, HER2-negative metastatic breast cancer in combination with fulvestrant. The Dublin-based company also has ongoing studies of samuraciclib in triple-negative breast cancer and prostate cancer.